RxDoctor Payments Data

Anusha Kalbasi, MD

Radiation Oncology · Stanford, CANPI 1851683684

Payments from drug & device makers

What this record shows

This record is dominated by grants: $36,932 of the $37,003 with a category attached, or 99.8%. Genentech, Inc. accounts for 99.8% of it on its own, with 1 other manufacturer making up the rest. Among radiation oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$37,003in general payments, 2019–2025

Across 3 payments — averaging $12,334 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$37K
  • E.r. Squibb & Sons, L.L.C.$71
$146,597in research payments, 2019–2025

Across 1 payment — averaging $146,597 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$147K

What the payments were for

  • Grants$36,932100%
  • Food & beverage$710%

General payments by program year

22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.2$36,932
E.r. Squibb & Sons, L.L.C.1$71

How this compares

$37,003 in reported general payments places this provider in the 95th percentile of 627 radiation oncology providers in California.

See all radiation oncology providers in California

Medicare billing

Part B allowed, 2024
$66,862
Medicare patients
105
Services billed
539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other radiation oncology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →